Literature DB >> 18157115

Reprogramming of human somatic cells to pluripotency with defined factors.

In-Hyun Park1, Rui Zhao, Jason A West, Akiko Yabuuchi, Hongguang Huo, Tan A Ince, Paul H Lerou, M William Lensch, George Q Daley.   

Abstract

Pluripotency pertains to the cells of early embryos that can generate all of the tissues in the organism. Embryonic stem cells are embryo-derived cell lines that retain pluripotency and represent invaluable tools for research into the mechanisms of tissue formation. Recently, murine fibroblasts have been reprogrammed directly to pluripotency by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield induced pluripotent stem (iPS) cells. Using these same factors, we have derived iPS cells from fetal, neonatal and adult human primary cells, including dermal fibroblasts isolated from a skin biopsy of a healthy research subject. Human iPS cells resemble embryonic stem cells in morphology and gene expression and in the capacity to form teratomas in immune-deficient mice. These data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18157115     DOI: 10.1038/nature06534

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1201 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

Review 2.  Nuclear reprogramming to a pluripotent state by three approaches.

Authors:  Shinya Yamanaka; Helen M Blau
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

3.  Alpha1 and beta1 integrins enhance the homing and differentiation of cultured prostate cancer stem cells.

Authors:  Satyanarayana Rentala; Prameela Devi Yalavarthy; Lakshmi Narasu Mangamoori
Journal:  Asian J Androl       Date:  2010-06-07       Impact factor: 3.285

Review 4.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

5.  An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility.

Authors:  Joan P Breyer; Daniel C Dorset; Travis A Clark; Kevin M Bradley; Tiina A Wahlfors; Kate M McReynolds; William H Maynard; Sam S Chang; Michael S Cookson; Joseph A Smith; Johanna Schleutker; William D Dupont; Jeffrey R Smith
Journal:  Am J Hum Genet       Date:  2014-02-27       Impact factor: 11.025

Review 6.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

7.  ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells.

Authors:  David A Claassen; Michelle M Desler; Angie Rizzino
Journal:  Mol Reprod Dev       Date:  2009-08       Impact factor: 2.609

Review 8.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

9.  Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame.

Authors:  Lijian Shao; Wei Feng; Yan Sun; Hao Bai; Jun Liu; Caroline Currie; Jaejung Kim; Rafael Gama; Zack Wang; Zhijian Qian; Lucy Liaw; Wen-Shu Wu
Journal:  Cell Res       Date:  2009-03       Impact factor: 25.617

10.  Critical regulation of miR-200/ZEB2 pathway in Oct4/Sox2-induced mesenchymal-to-epithelial transition and induced pluripotent stem cell generation.

Authors:  Guiying Wang; Xudong Guo; Wujun Hong; Qidong Liu; Tingyi Wei; Chenqi Lu; Longfei Gao; Dan Ye; Yi Zhou; Jie Chen; Jianmin Wang; Minjuan Wu; Houqi Liu; Jiuhong Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.